Strategic Diagnostics To Supply Reagents to Undisclosed IVD Manufacturer | GenomeWeb
NEW YORK (GenomeWeb News) – Strategic Diagnostics said today that it has signed an agreement to supply reagents to “a large manufacturer of in vitro diagnostics.”
 
The term of the agreement is five years, and the company said that it expects initial revenues of around $1 million per year, which are anticipated to “more than double” over the term of the agreement.
 
Strategic Diagnostics said it will begin shipping the reagents to the undisclosed client in the fourth quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.